AstraZeneca Vaccine - Product Scorecard

Company: AstraZeneca

Type: Covid-19 Vaccine
Product (brand name): AZD1222 (Covishield/Vaxzevria)
0%
compliance
with criteria
Share this score on social:

Other company scores

Bharat Biotech Vaccine
0%
Brii BioSciences Therapeutic
0%
CanSino Vaccine
0%
Celltrion Therapeutic
0%
CIGB Vaccine
0%
Texas Children’s Hospital Vaccine
0%
Finlay Vaccine
0%
Gamaleya Vaccine
0%
Gilead Therapeutic
0%
Johnson & Johnson Vaccine
0%
Moderna Vaccine
0%
Vaxine Vaccine
0%
Vektor Vaccine
0%
Zydus Vaccine
0%
AstraZeneca Antibody
0%
AstraZeneca Vaccine
0%
Eli Lilly Therapeutic 3
0%
Eli Lilly Therapeutic 2
0%
Eli Lilly Therapeutic 1
0%
MSD Therapeutic
0%
Novavax Vaccine
0%
Pfizer Therapeutic
0%
Pfizer Vaccine
0%
Regeneron Therapeutic
0%
Roche Therapeutic
0%
Sanofi Vaccine
0%
Sinopharm Vaccine
0%
Sinovac Vaccine
0%
GSK Therapeutic
0%
Explore the results of PAF’s research into the behaviour of AstraZeneca. Each section is given an overall score; individual criteria are also scored (see icon following the criteria heading).

Click on ‘Explanation about the score’ sign next to each entry to expand and learn more.

Category A: Commitments and Accountability

The company should publicly commit to human rights in relation to product development and marketing, by adopting an official human rights policy statement recognising the right to the highest attainable standard of health. The company should endeavour to integrate human rights into its strategies, policies, programmes, projects, and activities.

The company should also have a publicly available global access plan for their Covid-19 product, based on human rights standards, with measurable targets and lines of accountability.

A1: Does AstraZeneca publish a global access plan for its product?

AstraZeneca’s website states: “Our response to the COVID-19 pandemic, with a focus on low and middle-income countries, is one example of our equitable access strategy in action.” 

In its response to our questionnaire, the company mentions its collaboration with the Bill and Melinda Gates Foundation to enhance equitable access to Covid-19 medical products, and the fact that two thirds of its vaccines have gone to low- and middle-income countries, as well as 250 million doses delivered through COVAX. This is not published in a dedicated global access plan on their website.

See more company scores
Zydus Vaccine
ZFSW Vaccine
Vektor Vaccine
Vaxine Vaccine
Texas Children’s Hospital Vaccine
Sinovac Vaccine
Sinopharm Vaccine
Sanofi Vaccine
Roche Therapeutic
Regeneron Therapeutic
Pfizer Vaccine
Pfizer Therapeutic
Novavax Vaccine
MSD Therapeutic
Moderna Vaccine
Johnson & Johnson Vaccine
GSK Therapeutic
Gilead Therapeutic
Gamaleya Vaccine
Finlay Vaccine
Eli Lilly Therapeutic 3
Eli Lilly Therapeutic 2
Eli Lilly Therapeutic 1
CIGB Vaccine
Celltrion Therapeutic
CanSino Vaccine
Brii BioSciences Therapeutic
Bharat Biotech Vaccine
AstraZeneca Antibody
A2: Does AstraZeneca commit to comply with human rights standards in relation to product development and marketing?

AstraZeneca states that it is guided by the United Nations Guiding Principles on Business and Human Rights, the Universal Declaration on Human Rights, and the UN Global Compact (UNGC). 

“We commit to the Guiding Principles to respect human rights by acting with due diligence to avoid infringing on human rights and to address negative impacts. “We have ensured that the UNGC and its ten Principles have become part of our strategy, culture and day-to-day operations, and they will remain vitally important in the years ahead” —  Pascal Soriot, AstraZeneca CEO in a recommitment letter to the UNGC.

In its response to our questionnaire, AstraZeneca mentions that it is a member of Pharmaceutical Supply Chain Initiative (PSCI), and supports its principles for Responsible Supply Chain Management for ethics, labour, health and safety, environment, and related management systems. Finally, AstraZeneca also conducts human rights due diligence to assess the human rights risks of its activities.

 

See more company scores
Zydus Vaccine
ZFSW Vaccine
Vektor Vaccine
Vaxine Vaccine
Texas Children’s Hospital Vaccine
Sinovac Vaccine
Sinopharm Vaccine
Sanofi Vaccine
Roche Therapeutic
Regeneron Therapeutic
Pfizer Vaccine
Pfizer Therapeutic
Novavax Vaccine
MSD Therapeutic
Moderna Vaccine
Johnson & Johnson Vaccine
GSK Therapeutic
Gilead Therapeutic
Gamaleya Vaccine
Finlay Vaccine
Eli Lilly Therapeutic 3
Eli Lilly Therapeutic 2
Eli Lilly Therapeutic 1
CIGB Vaccine
Celltrion Therapeutic
CanSino Vaccine
Brii BioSciences Therapeutic
Bharat Biotech Vaccine
AstraZeneca Antibody

Category C: International cooperation

The company should constructively engage with international initiatives for the equitable distribution of vaccines and therapeutics, such as the Covid-19 Technology Access Pool (C-TAP) or the Medicines Patent Pool (MPP), and the ACT Accelerator (COVAX). The company should also publicly commit to not enforcing the exclusive rights of Covid-19 related patents, and enter into non-exclusive, transparent licensing agreements for its Covid-19 products with other companies.

C1: Does AstraZeneca commit to C-TAP or MPP?

When asked about AZ’s support of MPP or C-TAP at an IFPMA forum in May, CEO Pascal Soirot stated that ‘’intellectual property is a fundamental part of our industry and if you don’t protect IP, then essentially, there is no incentive for anybody to innovate.’’ AZ has not demonstrated any factual support to a responsible licensing mechanism.

Their response to our questionnaire had a similar message: Vaccines are highly specialized, complex biological products which are subject to rigorous testing and quality standards and processes during their development. Our approach has been to share our technology and know-how with experienced vaccine manufacturing organizations in countries where production can be set up or ramped up at scale. We believe this offers a more effective way of scaling up production and supporting innovation, and our model has enabled us to supply more than 2.5 billion doses to 170 countries around the world in just over a year since the first international approvals. To do this we enabled technology transfer to more than 20 different supply partners, including four sublicense agreements. Our sub-licensing agreement with Serum Institute of India (SII) supports the supply to India and to low and lower-middle income countries. Each of our sub-licensing agreements is thought out in detail to ensure it supports the best strategy for broad and equitable access.  Waiving IP rights completely would not solve the challenge of rapidly scaling up manufacturing to meet global demand. Rate-limiting factors include the time it takes to transfer the technical knowledge, skills and expertise to produce the vaccine, as well as the lack of specialized producers that can quickly set up the industrial capacity to make a safe and effective vaccine at scale.

See also Statnews article on this.

See more company scores
Zydus Vaccine
ZFSW Vaccine
Vektor Vaccine
Vaxine Vaccine
Texas Children’s Hospital Vaccine
Sinovac Vaccine
Sinopharm Vaccine
Sanofi Vaccine
Roche Therapeutic
Regeneron Therapeutic
Pfizer Vaccine
Pfizer Therapeutic
Novavax Vaccine
MSD Therapeutic
Moderna Vaccine
Johnson & Johnson Vaccine
GSK Therapeutic
Gilead Therapeutic
Gamaleya Vaccine
Finlay Vaccine
Eli Lilly Therapeutic 3
Eli Lilly Therapeutic 2
Eli Lilly Therapeutic 1
CIGB Vaccine
Celltrion Therapeutic
CanSino Vaccine
Brii BioSciences Therapeutic
Bharat Biotech Vaccine
AstraZeneca Antibody
C2: Does AstraZeneca commit to not enforcing the exclusive rights of Covid-19 related patents?

In its response to our questionnaire, AstraZeneca mentions that it has enabled technology transfer to over 20 supply partners across 15 countries, but this does not equate to a commitment not to enforce patents overall.

See more company scores
Zydus Vaccine
ZFSW Vaccine
Vektor Vaccine
Vaxine Vaccine
Texas Children’s Hospital Vaccine
Sinovac Vaccine
Sinopharm Vaccine
Sanofi Vaccine
Roche Therapeutic
Regeneron Therapeutic
Pfizer Vaccine
Pfizer Therapeutic
Novavax Vaccine
MSD Therapeutic
Moderna Vaccine
Johnson & Johnson Vaccine
GSK Therapeutic
Gilead Therapeutic
Gamaleya Vaccine
Finlay Vaccine
Eli Lilly Therapeutic 3
Eli Lilly Therapeutic 2
Eli Lilly Therapeutic 1
CIGB Vaccine
Celltrion Therapeutic
CanSino Vaccine
Brii BioSciences Therapeutic
Bharat Biotech Vaccine
AstraZeneca Antibody
C3: Does AstraZeneca supply to, or signs agreements with, the vaccines or therapeutics pillar of the ACT Accelerator?

AstraZeneca was the first pharmaceutical company to sign an agreement with COVAX in June 2020. It has agreements with the Serum Institute of India (SII), CEPI and GAVI to supply 400m doses to 92 AMCs through COVAX.

AstraZeneca states in its response to our questionnaire: “As of 14 January 2022, over 257 million AZ/SII doses have been delivered through COVAX to 130 countries. Over 204 million (79.36 %) of these doses have been delivered to LMIC/LICs. We put broad and equitable access at the heart of our response to the pandemic with approximately two thirds of our global supply of 2.5bn doses going to low and lower  middle income countries. We have facilitated the donation of over 200 million vaccines worldwide.”

See more company scores
Zydus Vaccine
ZFSW Vaccine
Vektor Vaccine
Vaxine Vaccine
Texas Children’s Hospital Vaccine
Sinovac Vaccine
Sinopharm Vaccine
Sanofi Vaccine
Roche Therapeutic
Regeneron Therapeutic
Pfizer Vaccine
Pfizer Therapeutic
Novavax Vaccine
MSD Therapeutic
Moderna Vaccine
Johnson & Johnson Vaccine
GSK Therapeutic
Gilead Therapeutic
Gamaleya Vaccine
Finlay Vaccine
Eli Lilly Therapeutic 3
Eli Lilly Therapeutic 2
Eli Lilly Therapeutic 1
CIGB Vaccine
Celltrion Therapeutic
CanSino Vaccine
Brii BioSciences Therapeutic
Bharat Biotech Vaccine
AstraZeneca Antibody
C4: Does AstraZeneca agree to license its Covid-19 medical products to other companies?

AstraZeneca has technology transfer agreements with over 20 different supply partners in over 15 countries, including 4 sublicensing agreements (FioCruz, SK Bioscience, R-Pharm, Siam Biosicence, Serum Institute of India, CEPI/GAVI)

See more company scores
Zydus Vaccine
ZFSW Vaccine
Vektor Vaccine
Vaxine Vaccine
Texas Children’s Hospital Vaccine
Sinovac Vaccine
Sinopharm Vaccine
Sanofi Vaccine
Roche Therapeutic
Regeneron Therapeutic
Pfizer Vaccine
Pfizer Therapeutic
Novavax Vaccine
MSD Therapeutic
Moderna Vaccine
Johnson & Johnson Vaccine
GSK Therapeutic
Gilead Therapeutic
Gamaleya Vaccine
Finlay Vaccine
Eli Lilly Therapeutic 3
Eli Lilly Therapeutic 2
Eli Lilly Therapeutic 1
CIGB Vaccine
Celltrion Therapeutic
CanSino Vaccine
Brii BioSciences Therapeutic
Bharat Biotech Vaccine
AstraZeneca Antibody

Category E: Equality, non-discrimination & equity

The company should engage in efforts to further equitable distribution of Covid-19 vaccines/therapeutics, by equitably distributing its supplies globally, devising fair pricing strategies, and making the active ingredient for its product available to other manufacturers. The company should also engage in full technology transfer to other manufacturers, including the necessary transfer of skills, legal components, knowledge and intellectual property. Where applicable, the company should agree to waive rights in regulatory test data, and refrain from enforcing TRIPS+ measures.

E1: Does AstraZeneca make the active ingredient available on reasonable grounds? [Only for therapeutics]

[Only applies to therapeutics]

See more company scores
Zydus Vaccine
ZFSW Vaccine
Vektor Vaccine
Vaxine Vaccine
Texas Children’s Hospital Vaccine
Sinovac Vaccine
Sinopharm Vaccine
Sanofi Vaccine
Roche Therapeutic
Regeneron Therapeutic
Pfizer Vaccine
Pfizer Therapeutic
Novavax Vaccine
MSD Therapeutic
Moderna Vaccine
Johnson & Johnson Vaccine
GSK Therapeutic
Gilead Therapeutic
Gamaleya Vaccine
Finlay Vaccine
Eli Lilly Therapeutic 3
Eli Lilly Therapeutic 2
Eli Lilly Therapeutic 1
CIGB Vaccine
Celltrion Therapeutic
CanSino Vaccine
Brii BioSciences Therapeutic
Bharat Biotech Vaccine
AstraZeneca Antibody
E2: Does AstraZeneca commit to full technology transfer to other manufacturers?

AstraZeneca commits to technology transfer, but with territorial restrictions. (FioCruz (Brazil) and others.

See more company scores
Zydus Vaccine
ZFSW Vaccine
Vektor Vaccine
Vaxine Vaccine
Texas Children’s Hospital Vaccine
Sinovac Vaccine
Sinopharm Vaccine
Sanofi Vaccine
Roche Therapeutic
Regeneron Therapeutic
Pfizer Vaccine
Pfizer Therapeutic
Novavax Vaccine
MSD Therapeutic
Moderna Vaccine
Johnson & Johnson Vaccine
GSK Therapeutic
Gilead Therapeutic
Gamaleya Vaccine
Finlay Vaccine
Eli Lilly Therapeutic 3
Eli Lilly Therapeutic 2
Eli Lilly Therapeutic 1
CIGB Vaccine
Celltrion Therapeutic
CanSino Vaccine
Brii BioSciences Therapeutic
Bharat Biotech Vaccine
AstraZeneca Antibody
E3: Does AstraZeneca commit to non-profit, ‘fair’, or differential pricing?

AstraZeneca agreed with Oxford University and Vaccitech to operate at a non-for-profit basis for the duration of the pandemic. Licensing agreement with FioCruz does however contain a provision saying that AstraZeneca may declare the pandemic over by 9 July 2021.

Now AstraZeneca is making a ‘modest’ profit – vaccines priced between 2 and 6 USD /dose. This remains affordable for most middle-income countries, and also includes a tiered pricing model which continues the commitment to provide the vaccine at no profit to low-income countries.

See also Donato Paolo Mancini and FioCruz & AstraZeneca, Technological Order Agreement Term № 01/2020.

See more company scores
Zydus Vaccine
ZFSW Vaccine
Vektor Vaccine
Vaxine Vaccine
Texas Children’s Hospital Vaccine
Sinovac Vaccine